Company intelligence / Profile preview
Keshihua
Nanjing, Jiangsu Sheng, Chinatcrxt.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting early phase 1 clinical trials for KSX-01 in solid tumors. One trial is recruiting (NCT05811975) to evaluate tolerance, safety, and preliminary efficacy of KSX01-TCRT Injection in solid tumor subjects. Another trial (NCT05447234) is not yet recruiting for advanced or recurrent gastric/Gastroesophageal Junction Cancer.
- Therapeutic areas
- Oncology
- Modalities
- TCR-T Cell therapyT-lymphocyte cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Keshihua.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keshihua.